[1] BLOEM B R,OKUN M S,KLEIN C.Parkinson's disease[J].Lancet,2021,397(10291):2284-2303.
[2] JELLINGER K A.Neuropathology of nonmotor symptoms of Parkinson's disease[J].Int Rev Neurobiol,2017,133:13-62.
[3] HIRSCH L,JETTE N,FROLKIS A,et al.The incidence of Parkinson's disease:a systematic review and meta-analysis[J].Neuroepidemiology,2016,46(4):292-300.
[4] 刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98-101.
[5] IBRAHIM N,KUSMIREK J,STRUCK A F,et al.The sensitivity and specificity of F-DOPA PET in a movement disorder clinic[J].Am J Nucl Med Mol Imaging,2016,6(1):102-109.
[6] 易畅,史新冲,冼文彪,等.18F-DOPA脑PET显像对早期帕金森病的诊断及病情评估[J].中华核医学与分子影像杂志,2018,38(11):731-735.
[7] KONG Y,ZHANG C,LIU K,et al.Imaging of dopamine transporters in Parkinson disease:a meta-analysis of (18) F/(123) I-FP-CIT studies[J].Ann Clin Transl Neurol,2020,7(9):1524-1534.
[8] LIU F T,GE J J,WU J J,et al.Clinical,dopaminergic,and metabolic correlations in Parkinson disease:a dual-tracer PET study[J].Clin Nucl Med,2018,43(8):562-571.
[9] LI X,ZHANG Q,QIN Y,et al.Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-beta-carbomethoxy-3-beta-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease[J].Medicine(Baltimore),2020,99(14):e19662.
[10] LI W,LAO-KAIM N P,ROUSSAKIS A A,et al.(11) C-PE2I and(18) F-Dopa PET for assessing progression rate in Parkinson's:a longitudinal study[J].Mov Disord,2018,33(1):117-127.
[11] KERSTENS V S,FAZIO P,SUNDGREN M,et al.Reliability of dopamine transporter PET measurements with [(18)F]FE-PE2I in patients with Parkinson's disease[J].EJNMMI Res,2020,10(1):95.
[12] DELVA A,VAN WEEHAEGHE D,VAN AALST J,et al.Quantification and discriminative power of (18)F-FE-PE2I PET in patients with Parkinson's disease[J].Eur J Nucl Med Mol Imaging,2020,47(8):1913-1926.
[13] DE NATALE E R,NICCOLINI F,WILSON H,et al.Molecular imaging of the dopaminergic system in idiopathic Parkinson's disease[J].Int Rev Neurobiol,2018,141:131-172.
[14] SANCHEZ-CATASUS C A,BOHNEN N I,YEH F C,et al.Dopaminergic nigrostriatal connectivity in early Parkinson disease:in vivo neuroimaging study of (11)C-DTBZ PET combined with correlational tractography[J].J Nucl Med,2021,62(4):545-552.
[15] PEREZ-LOHMAN C,KERIK N E,DIAZ-MENESES I E,et al.Diagnostic utility of [11C]DTBZ positron emission tomography in clinically uncertain parkinsonism:experience of a single tertiary center[J].Rev Invest Clin,2018,70(6):285-290.
[16] XU S S,ALEXANDER P K,LIE Y,et al.Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2(VMAT2) in clinically uncertain parkinsonian syndrome(CUPS):a 3-year follow-up study in community patients[J].BMJ Open,2018,8(11):e025533.
[17] SEGOVIA F,GORRIZ J M,RAMIREZ J,et al.Multivariate analysis of (18)F-DMFP PET data to assist the diagnosis of parkinsonism[J].Front Neuroinform,2017,11:23.
[18] PAGANO G,NICCOLINI F,FUSAR-POLI P,et al.Serotonin transporter in Parkinson's disease:a meta-analysis of positron emission tomography studies[J].Ann Neurol,2017,81(2):171-180.
[19] VIDAL B,LEVIGOUREUX E,CHAIB S,et al.Different alterations of agonist and antagonist binding to 5-HT1A receptor in a rat model of Parkinson's disease and levodopa-induced dyskinesia:a microPET study[J].J Parkinsons Dis,2021,11(3):1257-1269.
[20] VARRONE A,SVENNINGSSON P,FORSBERG A,et al.Positron emission tomography imaging of 5-hydroxytryptamine 1B receptors in Parkinson's disease[J].Neurobiol Aging,2014,35(4):867-875.
[21] LINDBERG A,NAG S,SCHOU M,et al.Development of a(18)F-labeled PET radioligand for imaging 5-HT1B receptors:[(18)F]AZ10419096[J].Nucl Med Biol,2019,78-79:11-16.
[22] VAN DER ZEE S,VALLEZ GARCIA D,ELSINGA P H,et al.[(18) F]Fluoroethoxybenzovesamicol in Parkinson's disease patients:quantification of a novel cholinergic positron emission tomography tracer[J].Mov Disord,2019,34(6):924-926.
[23] LDA B,MAA B,JPSB D,et al.Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation:an exploratory PET imaging study with [18F]-FEOBV[J].Parkinsonism Relat Disord,2021,91:162-166.
[24] LIU S Y,WILE D J,FU J F,et al.The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease:a cross-sectional PET study[J].Lancet Neurol,2018,17(4):309-316.
[25] KEPE V,BORDELON Y,BOXER A,et al.PET imaging of neuropathology in tauopathies:progressive supranuclear palsy[J].J Alzheimers Dis,2013,36(1):145-153.
[26] BUONGIORNO M,ANTONELLI F,COMPTA Y,et al.Cross-sectional and longitudinal cognitive correlates of FDDNP PET and CSF amyloid-beta and Tau in Parkinson's disease[J].J Alzheimers Dis,2017,55(3):1261-1272.
[27] MARQUIE M,NORMANDIN M D,MELTZER A C,et al.Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies[J].Ann Neurol,2017,81(1):117-128.
[28] SCHONHAUT D R,MCMILLAN C T,SPINA S,et al.(18)F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease:a multicenter study[J].Ann Neurol,2017,82(4):622-634.
[29] 李玲,刘丰韬,孙一忞,等.[18F]-APN-1607 tau蛋白PET显像在帕金森综合征中的初步临床应用[J].中国临床神经科学,2021,29(6):625-631.
[30] MEHRA S,SAHAY S,MAJI S K.Alpha-synuclein misfolding and aggregation:implications in Parkinson's disease pathogenesis[J].Biochim Biophys Acta Proteins Proteom,2019,1867(10):890-908.
[31] SHAHNAWAZ M,MUKHERJEE A,PRITZKOW S,et al.Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy[J].Nature,2020,578(7794):273-277.
[32] HELMICH R C,VAILLANCOURT D E,BROOKS D J.The future of brain imaging in Parkinson's disease[J].J Parkinsons Dis,2018,8(s1):S47-S51.
[33] SAEED U,LANG A E,MASELLIS M.Neuroimaging advances in Parkinson's disease and atypical parkinsonian syndromes[J].Front Neurol,2020,11:572976.
[34] KUEBLER L,BUSS S,LEONOV A,et al.[(11)C]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates[J].Eur J Nucl Med Mol Imaging,2021,48(6):1759-1772. |
